A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)

Summary

GFH312 could be a novel therapeutic option in the acute/chronic inflammatory process of atherosclerosis and provides potential beneficial effects to microvasculature function for PAD patients with IC in addition to preventing ischemia-reperfusion injury. This phase II study is designed to explore the clinical safety and efficacy of GFH312 after multiple oral doses, to support further development in patients with PAD or other atherosclerotic diseases.

Timeline

Start

2022-12-01

Primary completion

2023-12-31

Completion

2024-05-31

Outcome

Outcome not reported

Stopped (Business): “The study was terminated by sponsor for reasons of adjusted clinical development strategy.”

Drugs

Indications